Department of Microbiology, Immunology and Physiology, Meharry Medical College, Nashville, TN 37208, USA.
Int J Mol Sci. 2021 Jun 9;22(12):6236. doi: 10.3390/ijms22126236.
Excess lipid droplets are frequently observed in arterial endothelial cells at sites of advanced atherosclerotic plaques. Here, the role of tumor necrosis factor alpha (TNFα) in modulating the low-density lipoprotein (LDL) content in confluent primary human aortic endothelial cells (pHAECs) was investigated. TNFα promoted an up to 2 folds increase in cellular cholesterol, which was resistant to ACAT inhibition. The cholesterol increase was associated with increased I-LDL surface binding. Using the non-hydrolysable label, Dil, TNFα could induce a massive increase in Dil-LDL by over 200 folds. The elevated intracellular Dil-LDL was blocked with excess unlabeled LDL and PCSK9, but not oxidized LDL (oxLDL), or apolipoprotein (apoE) depletion. Moreover, the TNFα-induced increase of LDL-derived lipids was elevated through lysosome inhibition. Using specific LDLR antibody, the Dil-LDL accumulation was reduced by over 99%. The effects of TNFα included an LDLR cell surface increase of 138%, and very large increases in ICAM-1 total and surface proteins, respectively. In contrast, that of scavenger receptor B1 (SR-B1) was reduced. Additionally, LDLR antibody bound rapidly in TNFα-treated cells by about 30 folds, inducing a migrating shift in the LDLR protein. The effect of TNFα on Dil-LDL accumulation was inhibited by the antioxidant tetramethythiourea (TMTU) dose-dependently, but not by inhibitors against NF-κB, stress kinases, ASK1, JNK, p38, or apoptosis caspases. Grown on Transwell inserts, TNFα did not enhance apical to basolateral LDL cholesterol or Dil release. It is concluded that TNFα promotes LDLR functions through combined increase at the cell surface and SR-B1 downregulation.
在动脉内皮细胞的晚期动脉粥样硬化斑块部位,经常观察到过多的脂滴。在这里,研究了肿瘤坏死因子α(TNFα)在调节人主动脉内皮细胞(pHAEC)中低密度脂蛋白(LDL)含量中的作用。TNFα可促进细胞胆固醇增加 2 倍,而 ACAT 抑制作用则抵抗。胆固醇的增加与 I-LDL 表面结合增加有关。使用不可水解的标记物 Dil,TNFα 可诱导 Dil-LDL 增加 200 多倍。用过量未标记的 LDL 和 PCSK9 可阻断升高的细胞内 Dil-LDL,但不能阻断氧化 LDL(oxLDL)或载脂蛋白(apoE)耗竭。此外,通过溶酶体抑制作用,可升高 TNFα诱导的 LDL 衍生脂质的增加。使用特异性 LDLR 抗体,Dil-LDL 的积累减少了 99%以上。TNFα 的作用包括 LDLR 细胞表面增加 138%,ICAM-1 总蛋白和表面蛋白分别有非常大的增加。相比之下,清道夫受体 B1(SR-B1)的表达减少。此外,TNFα 处理的细胞中 LDLR 抗体结合速度快约 30 倍,诱导 LDLR 蛋白发生迁移变化。抗氧化剂四甲基硫脲(TMTU)可剂量依赖性抑制 TNFα 对 Dil-LDL 积累的影响,但对 NF-κB、应激激酶、ASK1、JNK、p38 或凋亡半胱天冬酶的抑制剂没有影响。在 Transwell 插入物上生长时,TNFα 不会增强 LDL 胆固醇或 Dil 的顶端至基底外侧释放。综上所述,TNFα 通过细胞表面的综合增加和 SR-B1 的下调来促进 LDLR 功能。